氨酸代谢作为MYC驱动的肝癌的可针对性漏洞
Tonatiuh Montoya1,2, Joyce V Lee1, Longhui Qiu3
1Department of Cell & Tissue Biology, University of California, San Francisco, CA, USA.
bioRxiv : the preprint server for biology
|August 6, 2025
概括
由MYC驱动的肝癌依赖于由GPT2调节的氨酸代谢来促进生长. 用L-cycloserine抑制GPT2有效地减少了小鼠模型中的瘤形成和生长,提供了一个新的治疗策略.
科学领域:
- 在瘤学瘤学.
- 代谢途径 代谢途径
- 癌症研究 癌症研究
背景情况:
- 肝癌是全球主要的健康问题,有效治疗方法有限.
- MYC过度表达与侵袭性,难以治疗的肝脏瘤有关.
- MYC重新编程癌细胞代谢,表明潜在的代谢漏洞.
研究的目的:
- 调查MYC是否诱导肝癌中的代谢依赖性,可以准.
- 为了确定对MYC驱动的肝脏瘤生长至关重要的特定代谢途径.
- 评估GPT2作为肝癌的潜在治疗标.
主要方法:
- 对MYC驱动的肝脏瘤进行对代谢酶表达的分析.
- 在肝脏瘤发生的小鼠模型中,GPT2的遗传消去.
- 在体内同位素追踪以研究氨酸代谢.
- 用GPT2抑制剂L-环素治疗小鼠模型.
主要成果:
- 由MYC驱动的肝癌利用依赖GPT2的氨酸代谢来进行生长.
- 在这些瘤中,GPT2是氨酸代谢的主要酶.
- 抑制GPT2显著降低了肝脏瘤的形成和生长.
- 氨酸为包括TCA循环,核酸合成和氨基酸合成在内的途径提供燃料.
结论:
- 由MYC驱动的肝脏瘤表现出对GPT2介导的氨酸代谢的依赖.
- 在MYC驱动的肝癌中,GPT2是一个可向的漏洞.
- L-Cycloserine证明了作为治疗肝癌这一子集的治疗剂的潜力.
更多相关视频
06:38An Oncogenic Hepatocyte-Induced Orthotopic Mouse Model of Hepatocellular Cancer Arising in the Setting of Hepatic Inflammation and Fibrosis
Published on: September 12, 2019
9.0K
07:38Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
Published on: June 6, 2025
269
相关概念视频
Targeted Cancer Therapies
7.8K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.8K
Adaptive Mechanisms in Cancer Cells
5.9K
Cancer cells accumulate genetic changes at an abnormally rapid rate due to the defects in the DNA repair mechanisms. From an evolutionary perspective, such genetic instability is advantageous for cancer development. Mutant cell lines accumulate a series of beneficial mutations that contribute to their progression into cancer.
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
5.9K
Abnormal Proliferation
4.6K
Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression
3.9K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.9K
Induced Pluripotent Stem Cells
4.4K
Stem cells are undifferentiated cells that divide and produce different cell types. Ordinarily, cells that have differentiated into a specific cell type are terminally differentiated; however, scientists have found a way to reprogram these mature cells so that they dedifferentiate and return to an unspecialized, proliferative state. These cells are pluripotent like embryonic stem cells—able to produce all cell types—and are called induced pluripotent stem cells (iPSCs).
Somatic...
Somatic...
4.4K
Treatment Resistant Cancers
3.4K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.4K
